388 results about "Rheumatic arteritis" patented technology

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The invention provides a rheumatoid arthritis patient low muscle quality risk prediction method based on an uncertainty perception stacked meta-learning structure, and belongs to the technical field of machine learning. The method comprises the following steps: acquiring a rheumatoid arthritis data set; constructing a base learner set comprising a table Transform class network and a gradient boosting tree class model; splicing the out-of-fold prediction probabilities of all the base learners and the statistics thereof to form a meta-feature matrix; taking the meta feature matrix as input, and constructing and training a meta learner comprising a spectrum normalization multilayer perceptron and a random feature Gaussian process output layer; collecting to-be-detected data, inputting the to-be-detected data into the trained base learner set and the trained meta learner in sequence, and performing temperature scaling and beta-calibration on a prediction result; and taking the calibrated prediction probability as a final prediction result. Through multi-source data fusion, the defects of an existing model in the aspects of practicability, probability reliability and the like are overcome.

The present application belongs to the technical field of medicine, and particularly relates to the use of tetrahydrojatrorrhizine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that tetrahydrojatrorrhizine can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis. Blood routine analysis shows that the administration of tetrahydrojatrorrhizine reduces the number of immune cells in the blood and weakens the immune level of the body. In addition, the experimental results also show that tetrahydrojatrorrhizine can inhibit synovial hyperplasia and relieve joint damage. Therefore, tetrahydrojatrorrhizine has the prospect of being developed into an oral medicament for treating rheumatoid arthritis, provides more treatment options for clinically treating rheumatoid arthritis, and has important social and economic values.

The invention discloses Witzia ciliaris NCU-33 and application thereof, and belongs to the technical field of microbial medicines. The bacillus coagulans NCU-33 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the bacillus coagulans NCU-33 is CGMCC NO.31779. The strain is separated from a fresh excrement sample of healthy people; the strain is capable of ameliorating and / or preventing rheumatoid arthritis by anti-inflammatory and immunomodulatory effects.

The invention discloses application of a diagnostic marker in preparation of a rheumatoid arthritis diagnostic product and a diagnostic system, and relates to the technical field of rheumatoid arthritis diagnosis. And the diagnostic marker comprises KMT2B, KMT2C, IFITM3, ECHS1, LYMPH%, MONO%, PDW, Path.CAST, RDW and RDW%. The diagnosis marker provided by the invention has extremely high diagnosis efficiency and has a good application prospect in the field of diagnosis of rheumatoid arthritis.

The invention provides an early-stage intelligent diagnosis method for rheumatoid arthritis based on a multi-modal medical image and deep learning, and the method comprises the steps: carrying out the image cleaning and standardization, automatic bone joint positioning and segmentation, and quality control of a multi-modal original data set, and obtaining a joint slice library; performing intra-modal self-supervised pre-training and cross-modal alignment representation, and then performing focus level detection and quantification to obtain a lesion feature vector of each joint; performing joint diagram construction and quality perception multi-modal fusion to obtain fusion feature representation, and performing weak supervision multi-instance learning and multi-task loss calculation based on the fusion feature representation to obtain an uncalibrated model; and carrying out model calibration and explainable output to obtain an intelligent diagnosis model. According to the method, the diagnosis time point can be advanced to the reversible inflammation stage, interpretable evidence of patient-level decision and joint-level quantification is provided, the engineering feasibility of small samples and multi-center generalization is considered, and the method has high clinical transformation potential.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

Provided is a bispecific antibody and use thereof, the bispecific antibody comprising: a first domain that specifically binds the interleukin-6 receptor IL-6R, and a second domain that specifically binds interleukin-23. The bispecific antibody can simultaneously target IL-6R and IL-23p19, with stronger specificity, more accurately targeting tumor cells and reducing the adverse effects of off-target toxicity and can perform a unique function to play a biological function that is difficult to achieve with monoclonal antibody drugs. Compared with monoclonal antibody combination therapies, it can also effectively reduce the cost of treatment and break the current upper limit of therapeutic efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and IBD.

The application relates to fused pyrimidinone derivatives of the general formula (I) which act as agonists of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) useful for the treatment of Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, amyotrophic lateral sclerosis, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion disease, and stroke.

The invention discloses a traditional Chinese medicine liniment for treating rheumatoid arthritis and a preparation process thereof, the traditional Chinese medicine liniment is composed of a wind-dispelling and pain-relieving liquid medicine and auxiliary materials, the wind-dispelling and pain-relieving liquid medicine contains eight traditional Chinese medicines of thorny elaeagnus root, erythrina bark, kadsura longepedunculata root, waxberry root, ardisia crenata, rose mallow root, glabrous sarcandra herb and wikstroemia canescens root, and is prepared by ultrasonic extraction; the auxiliary materials comprise polyvinyl alcohol, a chitosan-acetic acid solution, glycerol, azone, methylparaben, vanillyl butyl ether and ethanol. The liniment is short in film forming time and good in stability, has excellent transdermal absorption performance and antioxidant activity, can remarkably relieve joint swelling of RA model mice, improve the pain threshold value, improve joint pathological injuries, achieve local precise long-acting administration, reduce side effects of the whole body and improve patient compliance, is suitable for clinical treatment of RA, and has a wide application prospect. The problems that an existing rheumatoid arthritis treatment medicine is large in side effect, and a traditional Chinese medicine preparation is short in efficacy duration and inconvenient to use are solved.

The invention discloses a traditional Chinese medicine composition for treating arthralgia, a traditional Chinese medicine preparation and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine, and the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10-20 parts of vine of multiflower knotweed, 5-14 parts of rhizoma anemarrhenae, 10-20 parts of dandelion and 10-20 parts of bunge corydalis herb. The composition has a good treatment effect on rheumatoid arthritis, arthritis, arthralgia, muscular pain and the like caused by damp-heat, and can effectively solve the problem of limitation of existing medicines.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

The invention belongs to the technical field of medicines, and particularly relates to a triptolide nano-skeleton and a preparation method and application thereof, and the triptolide nano-skeleton comprises the following components by mass: 11%-20% of triptolide, 20%-60% of polyacrylic resin, and 20%-60% of mesoporous silica. The triptolide nano-skeleton provided by the invention is mainly composed of a drug triptolide, a high-molecular polymer material polyacrylic resin and a carrier material mesoporous silica, and a mixture formed by triptolide and polyacrylic resin is uniformly loaded on the mesoporous silica to form a solid preparation suitable for oral administration. The dissolution rate and oral absorption of the triptolide are remarkably increased, the treatment safety is ensured, meanwhile, the curative effect of the triptolide on rheumatoid arthritis is effectively enhanced, and the triptolide tablet has a good application prospect.

This invention relates to a novel use of IL-1β-ligand / IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and / or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and / or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and / or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.

Provided herein is a methods for monitoring inflammatory disease activity in a subject comprising: (i) obtaining a sample from the subject; and (ii) measuring an autoantibody concentration in the sample using an immunoassay. Optionally, the inflammatory disease is rheumatoid arthritis (RA). Optionally, the autoantibody is an anti-citrullinated vimentin autoantibody (anti-Sa) or an anti-carbamylated protein autoantibody (anti-CarP). Optionally, the autoantibody concentration is correlated to a multi-disease biomarker activity (MBDA) score. Also provided herein are systems and kits for performing the method described herein.

Disclosed is a selenium-containing polyamino acid having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, m, n, and x are as defined in the description. Also disclosed is a pharmaceutical composition containing the selenium-containing polyamino acid or a pharmaceutically acceptable salt thereof. Also disclosed is a use of the selenium-containing polyamino acid or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition containing the selenium-containing polyamino acid or the pharmaceutically acceptable salt thereof in the preparation of a drug for treating diseases selected from osteoarthritis, rheumatoid arthritis, and periodontitis. E[-(B)m-(A)n-D]x Formula (I)

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

This disclosure relates to RNAi agents capable of inhibiting complement factor B (CFB) gene expression. Pharmaceutical compositions containing CFB RNAi agents and methods of use thereof are also disclosed. The CFB RNAi agents disclosed herein may be conjugated to a targeted ligand containing an N-acetyl-galactosamine ligand to facilitate in vivo delivery to hepatocytes. RNAi agents can be used in methods of treating diseases, disorders, or conditions partially mediated by CFB gene expression, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), immune complex-mediated membrane proliferative glomerulonephritis (IC-MPGN), lupus nephritis (LN), anti-glomerular basement membrane antibody disease (anti-GBM), ischemia-reperfusion injury and T-cell-mediated rejection in kidney transplantation (TCMR), anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, age-related macular degeneration (AMD) including early and / or intermediate-stage AMD, geographic atrophy (GA), glaucoma, Doyne honeycomb retinal dystrophy, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pre-eclampsia, rheumatoid arthritis (RA), and / or other complement-mediated disorders.

The application belongs to the technical field of medicine, and relates to application of a pharmaceutical composition in preparation of a medicine for treating and / or preventing rheumatoid arthritis. The application provides application of a pharmaceutical composition in preparation of a medicine for treating and / or preventing rheumatoid arthritis, wherein the pharmaceutical composition comprises the following components: ginsenoside Rk1, ginsenoside Rg5, ginsenoside Rg3, ginsenoside Rh4, ginsenoside Rk3, ginsenoside ethanol-water extract and a pharmaceutically acceptable carrier. The components of the pharmaceutical composition can effectively treat and / or prevent rheumatoid arthritis.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The invention relates to a traditional Chinese medicine composition for treating wind-cold-dampness retention type rheumatoid arthritis, an application and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 85 to 95 parts of baked ginger, 12 to 18 parts of cortex cinnamomi, 25 to 35 parts of rhizoma arisaematis, 85 to 95 parts of radix paeoniae rubra, 25 to 35 parts of radix angelicae, 85 to 95 parts of radix aconiti agrestis, 7 to 11 parts of raw frankincense, 4 to 6 parts of raw myrrh, 7 to 11 parts of gallnut and 7 to 11 parts of semen brassicae. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention can be used for effectively treating wind-cold-dampness blocking type rheumatoid arthritis in an external application mode, and is high in safety, free of obvious toxic and side effects and remarkable in clinical application value.

The invention belongs to the field of medicine, and relates to a Keap1 degradation agent and a preparation method and application thereof, the Keap1 degradation agent is a compound shown in the formula I or pharmaceutically acceptable salt, optical isomer, stereoisomer or metabolite of the compound, and further, the invention further discloses application of the compound and a pharmaceutical composition of the compound in preparation of a medicine serving as the Keap1 degradation agent, and application of the Keap1 degradation agent in preparation of the medicine serving as the Keap1 degradation agent in preparation of the medicine serving as the Keap1 degradation agent in preparation of the medicine serving as the Keap1 degradation agent. The compound can be used for treating metabolic diseases, cardiovascular diseases, rheumatoid arthritis or steatohepatitis.

The present invention provides: a compound which is an antisense oligonucleotide capable of regulating the expression of a RasGRP4 gene and treating myositis and rheumatoid arthritis, and which has a nucleic acid base sequence consisting of 8-80 linked nucleosides and comprising at least 8 consecutive nucleic acid bases complementary to a transcript of RasGRP4; or a pharmacologically acceptable salt thereof.

The invention discloses application of guaiacol in treatment of rheumatoid arthritis, and particularly relates to application of guaiacol in preparation of drugs for treating rheumatoid arthritis. Cell experiments prove that guaiacol can effectively down-regulate expression of proinflammatory factors in macrophages and up-regulate expression of anti-inflammatory factors, and has remarkable anti-inflammatory activity; animal experiments show that the guaiacol effectively relieves rheumatoid arthritis model mouse diseases, and the specific manifestation is that the guaiacol obviously relieves the mouse claw swelling degree, reduces the arthritis disease score, obviously improves joint inflammatory cell infiltration, repairs cartilage injury, inhibits osteoclast generation and reduces the number of joint apoptotic cells; meanwhile, the level of proinflammatory factors in serum of mice can be effectively reduced, and the level of proinflammatory repair factors can be up-regulated. The invention proves that guaiacol has a definite curative effect on rheumatoid arthritis, good biological safety and no obvious side effect, provides a new effective active component for the treatment of rheumatoid arthritis, and has a good prospect of being developed into the medicine for treating rheumatoid arthritis.

1. The name of the design product: specific electromagnetic wave therapeutic instrument (HT-TDP-A). 2. The use of the design product: for physiotherapy and health care, such as auxiliary treatment for diseases such as soft tissue injury, rheumatoid arthritis, lumbar muscle strain, and pediatric diarrhea. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view. 5. The bottom of the design product is not easily visible or not visible during use, and the top view is omitted.